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Summary
Helicobacter pylori establishes a chronic lifelong
infection in the human gastric mucosa, which
may lead to peptic ulcer disease or gastric adeno-
carcinoma. The human beta-defensins (hβDs) are
antimicrobial peptides, hβD1 being constitutively
expressed in the human stomach. We hypoth-
esized that H. pylori may persist, in part, by
downregulating gastric hβD1 expression. We
measured hβD1 and hβD2 expression in vivo in
relation to the presence, density and severity of
H. pylori infection, investigated differential effects
of H. pylori virulence factors, and studied under-
lying signalling mechanisms in vitro. Significantly
lower hβD1 and higher hβD2 mRNA and protein
concentrations were present in gastric biopsies
from infected patients. Those patients with
higher-level bacterial colonization and inflamma-
tion had significantly lower hβD1 expression, but
there were no differences in hβD2. H. pylori infec-
tion of human gastric epithelial cell lines also
downregulated hβD1. Using wild-type strains and
isogenic mutants, we showed that a functional
cag pathogenicity island-encoded type IV secre-
tion system induced this downregulation. Treat-
ment with chemical inhibitors or siRNA revealed
that H. pylori usurped NF-κB signalling to modu-
late hβD1 expression. These data indicate that
H. pylori downregulates hβD1 expression via
NF-κB signalling, and suggest that this may
promote bacterial survival and persistence in the
gastric niche.
Introduction
Helicobacter pylori persistently infects the stomachs of
almost half the world’s population. Although the majority of
infected people remain asymptomatic, approximately
10–15% go on to develop peptic ulcer disease or gastric
cancers. The disease outcome of an infection is deter-
mined by a combination of bacterial, host and environmen-
tal factors (Blaser and Atherton, 2004; Robinson et al.,
2007; Atherton and Blaser, 2009). H. pylori expresses
numerous virulence determinants that have been linked to
disease, including the polymorphic vacuolating cytotoxin
gene A (vacA) and the cag pathogenicity island (cagPAI)
(Backert et al., 2010). H. pylori strains possessing toxic
alleles of vacA manipulate epithelial and immune cell
functions that contribute to disease. The cagPAI encodes a
type IV secretion system (T4SS) that binds α5β1 integrin on
host cells, penetrates and delivers the bacterial effector
protein CagA (Odenbreit et al., 2000; Kwok et al., 2007).
Once translocated into the cytosol, CagA activates specific
signalling pathways, including MAP kinase and NF-κB-
induced signalling. Both NF-κB p50/p65 heterodimers and
p65 or p50 homodimers undergo nuclear translocation
(Keates et al., 1997; Wada et al., 2001; Saha et al., 2008).
This leads to the expression of a variety of pro-
inflammatory and immune defence genes. The cagPAI
also allows translocation of soluble bacterial cell wall com-
ponents into the epithelial cytosol. These short-chain
peptidoglycan derivatives (disaccharide tripeptides) are
generated via activity of the lytic transglycosylase encoded
by slt (HP0645), an enzyme normally involved in
peptidoglycan remodelling. The disaccharide tripeptides
are recognized by nucleotide-binding oligomerization
domain 1 (NOD1), an intracellular sensor of Gram-
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negative bacteria, leading also to NF-κB-induced pro-
inflammatory signalling (Viala et al., 2004; Brandt et al.,
2005; Boughan et al., 2006). A third cagPAI-mediated
pathway has recently been described, where interaction of
CagL with the α5β1 integrin on epithelial cells also triggers
MAP kinase and NF-κB activation (Gorrell et al., 2013).
Bacterial factors therefore manipulate the gastric inflam-
matory response, which underlies the development of PUD
and gastric cancer.
Antimicrobial peptides (AMPs) are important in the host
response to infection. These small, cationic peptides are
expressed by a number of cell types including epithelial
cells. They can be subdivided into several categories, all of
which are potent and cytotoxic against bacteria but not
against normal mammalian cells (Guani-Guerra et al.,
2010). One group, the human β-defensins (hβDs), is a
crucial component of the host defence at mucosal epithelia
(Zasloff, 2002; O’Neil, 2003). Expression of hβD2 and
hβD4 is upregulated during H. pylori infection in a cagPAI-
dependent and NF-κB-mediated manner, and these AMPs
are known to have antimicrobial activity against the bacte-
rium (George et al., 2003; Boughan et al., 2006; Hornsby
et al., 2008; Otte et al., 2009). hβD3 also has bactericidal
activity against H. pylori and its expression is initially
upregulated by H. pylori infection in vitro (Boughan et al.,
2006), but subsequently downregulated in a CagA-
dependent manner during prolonged infection (Bauer
et al., 2012).
hβD1 (encoded by DEFB1) is constitutively expressed in
uninflamed normal tissue (Liu et al., 1997; O’Neil et al.,
2000), which highlights its importance in protection against
microbial infection. Expression in the GI tract (including the
gastric mucosa) is predominantly by epithelial cells rather
than inflammatory cells (Frye et al., 2000). One study
found increased hβD1 expression in the H. pylori infected
human gastric mucosa (Bajaj-Elliott et al., 2002), but a
second found decreased expression (Taha et al., 2005). In
a more recent study, a non-significant trend towards
reduced levels of hβD1 mRNA was found in gastric biop-
sies from infected patients (Vordenbaumen et al., 2010).
These studies, although somewhat contradictory, suggest
that H. pylori may modulate hβD1 expression. Consistent
with this idea are the observed binding motifs for multiple
transcription factors, including NF-κB, in the promoter
sequence of the DEFB1 gene (Liu et al., 1997; Zhu et al.,
2003; Prado-Montes de Oca et al., 2009).
Many AMPs also have chemotactic activity, working
together to direct immune effector cells to the site of
infection. Importantly, hβD1, hβD2 and hβD3 are associ-
ated with recruiting immature dendritic cells and memory T
cells via CC-chemokine receptor 6 (CCR6), hence repre-
senting a bridge between the innate and adaptive immune
responses (Yang et al., 2002). Cathelicidins have been
found to be involved in the recruitment of neutrophils,
in addition to circulating and tissue-derived monocytes
(De et al., 2000). AMPs therefore act to induce pro-
inflammatory immune responses, in some cases inducing
immune mediators that further induce the expression of
these AMPs, effectively creating a positive feedback loop
(Zasloff, 2007). Therefore, downregulation of hβD1 could
also mediate persistence of H. pylori infection by modulat-
ing the immune response.
The role of hβD1 during H. pylori infection is unclear
and modulation of hβD1 expression by both host and
bacterial factors may be possible. In this study, we there-
fore aimed to assess hβD1 expression levels in the
H. pylori infected gastric mucosa in comparison with
hβD2, to characterize the influence of H. pylori virulence
determinants on hβD1 expression, and to determine the
signalling pathways involved in regulating expression of
this defensin during infection.
Results
H. pylori infection is associated with reduced hβD1
expression in the human stomach in vivo
First, we assessed hβD1 (DEFB1) expression in the
human stomach in H. pylori infected and uninfected
patients, in comparison with hβD2 (DEFB4A) expression.
DEFB1 mRNA expression levels were threefold lower in
gastric biopsies from 31 H. pylori infected compared with
23 uninfected patients (P = 0.005; Fig. 1A). In agreement
with previous studies (Wada et al., 1999; Hamanaka et al.,
2001; Uehara et al., 2003; Boughan et al., 2006; Bauer
et al., 2013), DEFB4A expression levels were elevated in
H. pylori infected gastric biopsies (P = 0.001; Fig. 1A).
Median DEFB1 expression was twofold lower with cagA+
strain infections compared with cagA− infections, while
DEFB4A expression was significantly higher (P = 0.028
and P = 0.006 respectively; Fig. 1A). In a manner similar to
other studies on gastric mucosal defensins, to determine
differences in protein expression, gastric biopsies were
lysed and the concentrations of hβD1 and hβD2 were
quantified by ELISA (Bauer et al., 2013). As found by
RT-qPCR, hβD1 concentrations were significantly lower in
biopsies from 10 infected patients compared with five
uninfected patients (P = 0.001; Fig. 1B), while hβD2
protein concentrations were higher (P = 0.001). Lower
hβD1 and higher hβD2 concentrations were also detected
in the presence of a cagA+ infection (P = 0.016 and
P = 0.004 respectively; Fig. 1B).
Next, we examined associations of DEFB1 and DEFB4A
expression with the intensity of inflammation as assessed
by histopathology, scoring gastric antral tissue sections
from the H. pylori infected patients. Sixfold lower DEFB1
mRNA levels were observed in samples with grade 3
inflammation compared with those with grade 1 (P = 0.045;
hβD1 expression in Helicobacter pylori infection 2081
© 2013 The Authors. Cellular Microbiology published by John Wiley & Sons Ltd, Cellular Microbiology, 15, 2080–2092
Fig. 1C). There was an opposing trend but no significant
differences in DEFB4A expression. Finally, we investi-
gated the relationship between hβD1 and H. pylori coloni-
zation density in vivo, also by histopathology. A twofold
lower DEFB1 mRNA level was observed in samples with
grade 3 density compared with those with grade 1
(P = 0.009; Fig. 1D), suggesting a link between its expres-
sion and control of bacterial density. Again, no significant
differences were observed for DEFB4A expression.
hβD1 is downregulated in epithelial cells by pathogenic
strains of H. pylori in vitro
To assess hβD1 expression by epithelial cells in response
to H. pylori infection in vitro, we co-cultured the MKN7
human gastric epithelial cell line [reported to have the most
similar characteristics to normal human gastric mucosal
cells (Linden et al., 2007)] for 24 h with the cagPAI+ vacA
s1/m1 H. pylori strains 60190, 26695, 11637 and P12, and
the cagPAI− vacA s2/m2 strains Tx30a, J63 and J68 at a
multiplicity of infection (moi) of 100 bacteria per cell. ELISA
assays showed that mean hβD1 protein concentrations in
culture supernatants were consistently > 73% lower follow-
ing infection with the cagPAI+ strains compared with
uninfected cells (P < 0.001 for each; Fig. 2A), but no
effects were induced by any of the cagPAI− strains. This
result was confirmed for 60190 and Tx30a strains by
RT-qPCR (Fig. 2B). Conversely, in the same experiment
the cagPAI+ strains induced marked increases in hβD2
release (P < 0.01 for all; Fig. 2C) as previously reported
Fig. 1. Analysis of hβD1 and hβD2 expression during H. pylori infection in vivo. Levels of DEFB1 and DEFB4A mRNA were measured in the
gastric mucosa of 23 uninfected and 31 H. pylori infected donors (A: *P = 0.005 and P = 0.001 respectively), and compared according to cagA
genotype status of the colonizing strain (A: *P = 0.028 and P = 0.006 respectively). hβD1 and hβD2 protein concentrations in gastric biopsies
from five uninfected and 10 H. pylori infected donors were measured (B: *P = 0.001 and P = 0.001), and concentrations in five cagA+ and five
cagA− biopsies were also compared (B: *P = 0.016 and P = 0.004). Expression levels were also stratified based on histological inflammation
scores graded from gastric biopsy tissue sections as mild (score of 1, n = 6), moderate (score of 2, n = 20) or substantial (score of 3, n = 5)
(C: *P = 0.045). Data were also stratified according to bacterial density scores: mild (score of 1, n = 13), moderate (score of 2, n = 5) or
substantial colonization (score of 3, n = 13) (D: *P = 0.001). RT-qPCR data were normalized against GAPDH and expressed relative to
measurements from an uninfected tissue comparator. Protein concentrations were calculated per mg of total protein. Boxes represent the first
and third quartiles with median values shown as a horizontal line within the box. Whiskers represent the lowest and highest observations
within 1.5 times the first and third quartile.
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(Wada et al., 1999; O’Neil et al., 2000; Uehara et al.,
2003). To demonstrate that the findings were not a cell
line-specific anomaly, we also conducted experiments with
AGS cells in parallel and obtained similar results, although
lower concentrations of defensins were detected (Fig. 2D–
F). These data show that pathogenic H. pylori strains
potently downregulate hβD1 expression by different gastric
epithelial cell lines.
The H. pylori cagPAI induces hβD1 downregulation
As we observed hβD1 downregulation in vitro only when
cells were infected with cagPAI+ vacA s1/m1 H. pylori
strains, we next aimed to determine which bacterial genes
influenced the expression of hβD1. To achieve this, hβD1
protein and mRNA expression levels were assessed when
MKN7 or AGS cells were co-cultured with the wild-
type strain 60190 (60190WT), or its isogenic mutants
60190ΔcagE (which does not express the cagPAI-encoded
T4SS), 60190ΔcagA (which expresses the T4SS but does
not translocate CagAinto host cells) and a vacA null mutant
(60190ΔvacA). The reduction in hβD1 in MKN7 and AGS
cells was less marked for the 60190ΔcagE mutant
than 60190WT (significant difference in AGS cells
only, P = 0.01) indicating that the cagPAI contributed to
hβD1 downregulation. However, the 60190ΔcagA strain
downregulated hβD1 by a similar extent to the wild-type
strain, for both mRNA and protein levels, showing that the
injected T4SS effector protein CagA was not involved in
this process (Fig. 3A, C and D). We also found no differ-
ence in hβD1 expression from co-culture of epithelial cell
lines with the 60190ΔvacA mutant (Fig. 3A, C and D). As a
control for the performance of the mutants in the assays,
IL-8 concentrations were also measured. Effects of all
mutants were in line with previous reports (Viala et al.,
2004; Argent et al., 2008; Gorrell et al., 2013) (Fig. 3B).
As H. pylori peptidoglycan processed by the lytic
transgycosylase Slt has also been reported to be
Fig. 2. Analysis of hβD1 expression during H. pylori infection in vitro. MKN7 (A–C) and AGS (D–F) cell lines were infected with H. pylori
strains 60190, 11637, 26695, P12 (all cagA positive and expressing the s1/m1 form of vacA), and Tx30a, J63, J68 (cagPAI−, vacA s2/m2) for
24 h. hβD1 and hβD2 protein concentrations in culture supernatants were measured by ELISA (A, C, D and F). hβD1 mRNA expression was
measured by RT-qPCR (B and E), and data presented as fold differences relative to that measured in uninfected cells. Bars depict mean
expression levels from three independent experiments and error bars show standard deviations. The asterisk (*) indicates a significant
difference in expression compared with uninfected cells (P < 0.01).
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translocated into epithelial cells via the cagPAI-encoded
T4SS, inducing activation of NOD1, NF-κB signalling and
secretion of the pro-inflammatory cytokine IL-8 (Viala et al.,
2004), we investigated whether this process contributed to
hβD1 downregulation. Cells were cultured with an slt
(HP0645) null mutant derived from H. pylori strain 26695
(26695Δslt) (Viala et al., 2004; Chaput et al., 2007). This
mutant generates up to 40% less cell wall disaccharide
tripeptide than the wild-type (26695WT) but has compara-
ble growth rates with the wild-type strain and has no
defects in the formation of the T4SS. We showed that
the 26695Δslt strain induced significantly less hβD1
downregulation compared with 26695WT in MKN7 and
AGS cells (P = 0.01) but this did not completely reverse the
effect (Fig. 3A and C).
Finally we co-cultured cells with a complete cagPAI null
mutant derived from the P12 strain (P12ΔcagPAI), and
confirmed that levels of hβD1 expression were similar to
that observed in uninfected cells. Similarly a cagL null
mutant (P12ΔcagL), in which the T4SS is incapable
of interacting with epithelial cells via α5β1 integrin, did
not downregulate hβD1 expression. These results show
that the cagPAI induces hβD1 downregulation, possibly
through CagL-α5β1 integrin interactions and delivery of cell
wall disaccharide tripeptides, rather than via delivery of
CagA.
H. pylori usurps NF-κB signalling to downregulate hβD1
We next aimed to determine the intracellular signalling
pathways through which H. pylori regulates hβD1 expres-
sion. Sequence analysis of the DEFB1 gene identified
binding sites in the promoter for NF-κB1 (p50 subunit of
NF-κB) and Activator Protein (AP)-1 (Prado-Montes de
Oca, 2010), which implies regulation of hβD1 transcription
through NF-κB and/or MAP kinase signalling. Given the
observed association between the cagPAI and hβD1
expression, we investigated the role of NF-κB and the
individual ERK, p38 and JNK MAP kinase signalling path-
ways in hβD1 downregulation during infection. AGS and
MKN7 cells were cultured with H. pylori strain 60190WT in
the presence of specific drug inhibitors of each pathway
respectively. Effects on DEFB1 mRNA, and hβD1 and
hβD2 protein were examined (Fig. 4). Uninfected cells
Fig. 3. The effect of bacterial virulence factors on hβD1 expression in vitro. MKN7 (A and B) and AGS cells (C and D) were infected with
H. pylori strains Tx30a, 60190WT, 60190ΔcagA, 60190ΔcagE, 60190ΔvacA, 26695WT, 26695Δslt, P12WT, P12ΔcagL and P12ΔcagPAI
(moi = 100). hβD1 (A and C) and IL-8 (B) concentrations in culture supernatants were measured by ELISA after 24 h. The asterisk (*)
indicates a significant difference in concentration when comparing effects of mutant strains to their parental strain 60190WT, 26695WT or
P12WT (P < 0.01). Fold differences in hβD1 mRNA expression relative to uninfected cells were quantified by RT-qPCR (D). The asterisk (*)
indicates a significant difference in expression level compared with 60190WT-infected cells (P < 0.05). Bars represent the mean of three
independent experiments and error bars show standard deviations.
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were treated with recombinant TNFα as a positive control
for activation of NF-κB, and this reduced DEFB1 expres-
sion, reduced hβD1 secretion (P = 0.001), and increased
hβD2 release compared with untreated cells (P = 0.01).
As previously, the 60190WT strain reduced hβD1 and
increased hβD2 expression. The ERK, p38 and JNK
kinase inhibitors had a slight but no significant impact on
H. pylori-induced hβD1 downregulation. In contrast, the
NF-κB inhibitor blocked these effects significantly (two- to
fourfold difference in hβD1 concentrations between cul-
tures infected with 60190WT in the presence and absence
of NF-κB inhibitor; P = 0.05 and P = 0.01 in AGS and
MKN7 cells respectively; Fig. 4B and C). These results
confirm the importance of the NF-κB signalling pathway in
H. pylori-modulated expression of hβD1 expression.
To confirm the data and investigate the mechanisms
further, small interference RNA (siRNA) experiments were
performed to silence expression of NFKB1 (which encodes
the NF-κBp50 subunit), and RELA (NF-κBp65 subunit).
MAPK1 siRNA duplexes were also tested since the MAP
kinase pathway is known to be stimulated by cagA-
independent cagPAI signalling. Western blots confirmed
the gene knock-downs (Fig. S1). 60190WT-infected cells
previously treated with NFKB1 or RELA siRNA expressed
two- to fivefold higher concentrations of hβD1 compared
with those treated with negative control duplexes (P < 0.05
for both siRNAs in MKN7 and AGS cells; Fig. 5A and D).
hβD2 expression in H. pylori-infected MKN45 cells is
reportedly controlled by the p65 homodimeric form of
NF-κB (Wada et al., 2001). Threefold lower concentrations
of hβD2 were detected following RELA silencing in both cell
lines (P < 0.05); effects of NFKB1 siRNA were less marked
(Fig. 5B and E). RELA silencing also had a dramatic effect
on IL-8 responses, but NFKB1 siRNA had no effect
(Fig. 5C and F). MAPK1 siRNA treatment also had an
effect on H. pylori-induced hβD1 expression, with signifi-
cantly increased concentrations in AGS cell supernatants
(P = 0.05). These data confirm the importance of NF-κB in
the H. pylori-mediated downregulation of hβD1 expression
and upregulation of hβD2 expression. They also indicate
some involvement of the ERK pathway.
Discussion
Antimicrobial peptides play a vital role during infection,
acting as a key line of defence against invading microbes
and also as essential components in modulating the
immune response to infections. While expression of hβD2
and hβD4 is inducible and upregulated in response
to H. pylori infection, hβD1 is normally constitutively
expressed by epithelial cells in the absence of H. pylori.
Mice with a deletion in the homologous mBD1 gene have
an impaired capacity to combat bacterial infections
(Morrison et al., 2002; Moser et al., 2002), reflecting the
Fig. 4. Assessing the signalling pathways involved in modulation
of hβD1 expression in vitro, using inhibitor drugs. Expression
of hβD1 mRNA (A) and protein (B and C), and also hβD2
protein (D) was assessed after treating 60190WT H. pylori
infected AGS (A and B) and MKN7 (C and D) cells with
6-amino-4-(4-phenoxyphenylethylamino)quinazoline (NF-κB
activation inhibitor), SP600125 (JNK inhibitor), U0126 (MEK1
inhibitor), or SB203586 (p38 inhibitor), prior to and during
incubation. Treatment with the drug diluent alone was included as a
negative control. TNFα treatment was included as a positive control
inducer of NF-κB activation. mRNA expression levels are given as
a fold difference relative to uninfected and untreated cells. *hβD1
significantly higher and hβD2 lower in NF-κB inhibitor-treated cells,
compared with controls (P < 0.05). **hβD1 significantly lower and
hβD2 higher in TNFα-treated, compared with untreated cells
(P < 0.05). Bars represent the mean from three independent
experiments and error bars show standard deviations.
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importance of this AMP as a component of the innate
anti-bacterial immune response. However, there is conflict
in the literature concerning how hβD1 is differentially
expressed during H. pylori infection (Bajaj-Elliott
et al., 2002; Taha et al., 2005; Kocsis et al., 2009;
Vordenbaumen et al., 2010). In agreement with the study
by Taha et al., we found that mRNA expression of hβD1
was downregulated in the H. pylori-infected human gastric
mucosa and also in infected gastric epithelial cells in vitro.
Two studies reporting upregulated hβD1 expression in
infected epithelial cell lines in vitro used the same primer
sequences (Bajaj-Elliott et al., 2002; Kocsis et al., 2009).
When we performed additional tests using these however,
the trends in our data remained the same, i.e. hβD1 expres-
sion was downregulated by infection by functional T4SS
cagPAI+ H. pylori (data not shown). We were also able to
confirm our findings using ELISA to quantify hβD1 protein
both in gastric biopsy tissue and in culture supernatants,
which validates our mRNA data.
Our data show that hβD1 expression is modulated
during H. pylori infection. Downregulation of hβD1 expres-
sion has previously been observed in the intestinal
mucosa of patients infected with Shigella dysenteriae
(Islam et al., 2001), or those with Crohn’s disease or
ulcerative colitis (Wehkamp et al., 2003). There is also a
precedent for hβD1 downregulation in epithelial cells in
vitro. Culturing intestinal epithelial cells with the enteric
pathogens Vibrio cholerae, enterotoxigenic Escherichia
coli and S. dysenteriae suppressed hβD1 expression in a
manner involving protein kinase A and ERK MAP kinase
signalling (Chakraborty et al., 2008). Infections of airway
and gingival epithelial cells with influenza virus, Herpes
simplex virus 1 and Sendai virus was also recently
reported to downregulate hβD1 expression. This process
Fig. 5. Assessing the signalling pathways involved in modulation of hβD1 expression in vitro, using gene silencing. hβD1 (A and D), hβD2
(B and E) and IL-8 (C and F) concentrations 24 h after infecting MKN7 (A–C) and AGS (D–F) cells with 60190WT H. pylori. Cells were
pre-treated 48 h previously with siRNA duplexes in HiPerfect transfection reagent (HF). siRNA treatments targeted the NFKB1 (NFκBp50),
RELA (NFκBp65) and MAPK1 genes. Negative control duplexes were non-silencing, whereas positive control duplexes targeted genes
necessary for cell survival. *Significantly different concentration compared with cells treated with negative control siRNA (P < 0.05). Bars
represent the mean from three independent experiments and error bars show standard deviations.
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required live virus, but the mechanism remains unknown
(Ryan et al., 2011).
We found that cagPAI+ wild-type strains markedly sup-
pressed hβD1 expression, while three cagPAI− strains
consistently did not. Analysis of bacterial factors demon-
strated that hβD1 downregulation was cagA independent.
Although our gastric biopsy data showed lower hβD1
expression in those infected with cagA+ strains, we have
merely used this as a marker for presence of the cagPAI. In
vitro, hβD1 downregulation was completely abrogated in
cells infected with cagPAI- or cagL-deficient mutants, and
partially reversed with the slt mutant. This indicated that
the suppression was mediated by T4SS engagement
of the α5β1 integrin and NOD1 activation in epithelial
cells. We then investigated NF-κB- and MAPK-dependent
downregulation of hβD1, given the known action of
cagPAI-containing strains upon these signalling pathways
(Brandt et al., 2005). Interestingly, increased hβD1 expres-
sion was observed when NF-κB signalling was inhibited,
and was reduced with TNFα-mediated NF-κB activation.
NF-κB response elements have been described in the
DEFB1 promoter sequence (Prado-Montes de Oca et al.,
2009). The role of H. pylori induced NF-κB signalling in the
suppression rather than induction of gene expression is
somewhat unusual, but not unknown. For example, sup-
pression of H,K-ATPase expression, the enzyme mediat-
ing gastric acid secretion, was observed in H. pylori
infected AGS cells and found to involve T4SS-dependent,
CagA-independent NF-κB activation (Saha et al., 2008;
2010).
The NF-κB family of transcription factors consists of five
members, and NF-κB exists as a homo- or heterodimer of
these subunits. Of these, p50 and p52 lack the transcrip-
tion activation domain necessary for transcription. Binding
of these homodimers to a promoter can block transcription
of the target gene (Hayden and Ghosh, 2008). Saha et al.
showed that infection of AGS cells with a cagPAI+ strain of
H. pylori induced transfer of both homodimeric p50/p50
and heterodimeric p65/p50 forms to the nucleus. Expres-
sion of H,K-ATPase was repressed by the binding of p50/
p50 NF-κB to the HKα promoter (Saha et al., 2008). The
DEFB1 gene promoter is known to have a p50-binding
domain, therefore p50 homodimers or p65/p50 hetero-
dimers could potentially bind (Prado-Montes de Oca et al.,
2009). We found that silencing of NFBK1 and RELA
equivalently prevented the inhibition of hβD1 expression,
therefore each of these genes plays a role and the inhibi-
tory effect of p50 homodimers appears a less likely expla-
nation. Another possibility is that NF-κB activation (p65/
p50) stimulates expression of host factors which then block
hβD1 gene expression, for example olfactomedin 4, which
inhibits NF-κB activation in a feedback mechanism involv-
ing NOD1 (Liu et al., 2010a), and various microRNAs (Xiao
et al., 2009; Tang et al., 2010; Liu et al., 2010b). Our
finding that hβD1 suppression could be induced by TNFα,
which is known to stimulate activation and nuclear trans-
location of NF-κBp65 in AGS cells (Robinson et al., 2008),
is novel and adds weight to this theory. TNFα could also be
exerting an effect on defensin expression in the stomach,
and it would be interesting to test this using animal models.
Incubation of other types of epithelial cells with NF-κB
inhibitors or TNFα has not been shown to influence hβD1
expression (Zhao et al., 1996; O’Neil et al., 1999; Joly
et al., 2005); however, defensin responses are known to be
cell line dependent (Grubman et al., 2010).
As a further control for our experiments, we measured
expression of the more widely studied defensin hβD2. In
accordance with others, we found this to be increased in
response to H. pylori both in vivo and in vitro (Wada et al.,
1999; Boughan et al., 2006; Bauer et al., 2013), and
increased further with cagPAI+ strains (Hornsby et al.,
2008; Grubman et al., 2010). Bauer et al. found that
although DEFB4 mRNA was elevated in the infected
gastric mucosa, this trend could not be shown with protein
concentrations (Bauer et al., 2013). The defensin concen-
trations detected in our study were lower, possibly because
we used a buffer with a lower detergent content when
preparing the lysates (Staples et al., 2013). This possible
explanation for the discrepant results between the studies
warrants further investigation. Our mechanistic data on
hβD2 agreed with that of Grubman et al., who found that
NOD1 activation induced by cagPAI+ strains induced
DEFB4 mRNA expression in AGS cells. Interestingly they
showed that DEFB4 expression could also be induced in
HEK293 cells by stimulation with TNFα (Grubman et al.,
2010). We found similar trends to our in vivo data using two
different cell lines, and also confirmed the findings of
others. This is very encouraging, but further studies are
needed with a wider range of cell types, and using other
methods, e.g. luciferase reporter assays of DEFB1 and
DEFB4 gene promoter activity, and immunohistochemistry
analysis of biopsy tissues. Using a defensin ELISA on
whole biopsy lysates does not take account of the possi-
bility that increased inflammatory cells in infected tissue
influenced the findings, which were normalized for total
protein content. The range of biopsy protein concentrations
among the groups, however, were similar.
We have shown that epithelial cell hβD1 expression is
downregulated during H. pylori infection, but the impor-
tance of such modulation is still not completely clear. It has
recently come to light that hβD3 expression is also sup-
pressed during prolonged H. pylori infection of AGS cells
via a CagA-dependent mechanism, and that its expression
in vivo is also reduced in gastric biopsies from infected
patients (Bauer et al., 2012; 2013). The fact that high
colonization densities in vivo correspond with lower hβD1
expression indicates that reducing the level of hβD1 may
contribute to the persistence of the bacterium in the gastric
hβD1 expression in Helicobacter pylori infection 2087
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mucosa, but a role for hβD3 suppression is also likely to be
important. Additionally, hβD1 bactericidal activity has been
reported to be synergistic with hβD2 and the cathelicidin
LL-37 (George et al., 2003; Hase et al., 2003), both of
which have bactericidal activity against the bacterium.
Therefore, downregulation of hβD1 may also limit the
consequences of hβD2 and LL-37 activity, providing an
additional benefit over merely reducing hβD1 expression.
In conclusion, we have demonstrated an NF-
κB-dependent downregulation of hβD1 expression
during H. pylori infection, which was dependent on
CagA-independent cagPAI signalling. In agreement with
the in vitro experiments, lower-level expression of hβD1 in
the infected human gastric mucosa was significantly asso-
ciated with cagPAI+ strains, more severe inflammation and
higher colonization densities. We suggest that H. pylori-
induced modulation of hβD1 expression may contribute to
the persistence of H. pylori in the gastric mucosa.
Experimental procedures
Tissue samples
Antral gastric biopsies were donated by 31 H. pylori-infected and
23 uninfected patients attending the University Hospital, Notting-
ham, for routine upper gastrointestinal endoscopy, with informed
written consent and approval from the Nottingham Research
Ethics Committee. H. pylori status was determined by rapid
urease test, bacterial culture and histology. Samples were not
collected from patients taking proton pump inhibitors, non-
steroidal anti-inflammatory drugs, or antibiotics in the 2 weeks
preceding endoscopy. Bacterial isolates were PCR-genotyped for
cagA status as previously described (Hussein et al., 2008).
Biopsy specimens for histology were formalin-fixed, paraffin-
embedded, cut to 4 μm thickness, and stained with haematoxylin
and eosin or toluidine blue for assessment of inflammation and
H. pylori colonization density respectively. Grading was carried
out using the modified Sydney Scoring System (0 = not present,
1 = mild, 2 = moderate and 3 = substantial) by an experienced
histopathologist (AMZ) who was blinded to other data (Genta and
Dixon, 1995). Biopsies for RNA analysis were immediately pre-
served in RNAlater (Sigma-Aldrich, UK).
Gastric biopsy lysates
Gastric biopsies from five uninfected and 10 infected patients
(five with cagA+ strains) were homogenized according to a pre-
viously described method (Staples et al., 2013). Single biopsies
were suspended in 300 μl PBS containing 2 mM Mg2+ (Sigma),
25 U ml−1 Benzonase® nuclease (Novagen, Germany), and pro-
tease inhibitors (complete mini [EDTA-free], Roche, Germany),
processed on ice using disposable pestles and filter tips.
Samples were clarified by centrifugation at 10 000 g for 10 min at
4°C. Supernatants were aliquoted into LoBind tubes (Eppendorf),
tested for total protein concentration using a bicinchoninic
acid (BCA) assay kit (Pierce, IL, USA), and stored at −80°C.
Supernatants from infected and uninfected donors contained
similar protein concentrations (medians 1.77 and 1.54 mg ml−1
respectively).
Cell lines and bacterial strains
The human gastric epithelial MKN7 cell line (kind gift from Dr
Sara Linden, University of Gothenburg, Sweden) was maintained
in RPMI1640 medium supplemented with 10% heat-inactivated
fetal bovine serum (FBS) (Sigma-Aldrich). AGS cells (ATCC
CRL-1739™) were grown in nutrient mixture F12 Ham supple-
mented with 10% FBS and 2 mM L-glutamine (Sigma-Aldrich). All
cell lines were incubated at 37°C in a 5% CO2 humidified atmos-
phere. cagPAI+ H. pylori strains 60190, 11637, 26695, P12 and
cagPAI− isolates Tx30a, J63 and J68 (Boughan et al., 2006;
Corcoran et al., 2007; Keates et al., 2007) were cultured on
Blood agar base 2 containing 5% (v/v) horse blood (Oxoid, Cam-
bridge, UK) at 37°C under microaerobic conditions (Argent et al.,
2004). Isogenic mutants deficient in vacA (60190ΔvacA), cagA
(60190ΔcagA) and cagE (60190ΔcagE) derived from the 60190
strain (Argent et al., 2008), cagPAI- and cagL-deficient mutants
(P12ΔcagPAI and P12ΔcagL) derived from the P12 strain (Kwok
et al., 2007), and an slt deletion mutant (26695Δslt) derived from
the 26695 strain [kindly donated by Dr Richard Ferrero, Monash
University, Victoria, Australia (Viala et al., 2004)], were also used.
In vitro culture experiments
Using methods based on those of Bajaj-Elliott et al. (2002),
5 × 104 MKN7 or AGS cells per well were seeded in 24-well
culture plates with the appropriate medium and allowed to adhere
at 37°C in a 5% CO2 air-humidified atmosphere for 24 h. The
medium was replaced with a suspension of H. pylori at a multi-
plicity of infection of 100 bacteria per epithelial cell, and cultures
were incubated for a further 24 h. Multiplicities of infection were
confirmed by viable counting. For quantification of defensins and
IL-8 concentrations in supernatants, 1 × 105 epithelial cells per
well were seeded, and co-cultures were carried out using serum-
free F12 medium.
Defensin and IL-8 ELISA assays
After co-culture of epithelial cells with H. pylori, supernatants
were aliquoted, frozen at −80°C and thawed once only. Biopsy
lysates were thawed and tested immediately for defensins. hβD1
and hβD2 assays were performed using Human BD-1 and BD-2
ELISA Development Kits (PeproTech, UK) and IL-8 concentra-
tions were determined with a Human IL-8 CytoSet™ ELISA
(Invitrogen), according to manufacturers’ instructions and with a
standard curve on each plate. Typical sensitivity limits (mean plus
3 standard deviations of six replicate 0 pg ml−1 control wells) were
0.5 pg ml−1 hβD1, 4.5 pg ml−1 hβD2 and 5.1 pg ml−1 IL-8.
Reverse transcriptase PCR (RT-qPCR)
RNA was extracted from antral gastric biopsies and cell lines
using an RNeasy Mini kit (QIAGEN, Crawley, UK) according to
the manufacturer’s instructions. cDNA was generated from
100 ng RNA using Superscript reverse transcriptase II, with oligo
(dT) primers (Invitrogen). Real-time PCR was performed using
the Rotor-Gene 3000 real-time PCR system (QIAGEN). First
stage RT-PCR samples, produced in the absence of reverse
transcriptase from each RNA sample, were tested in parallel to
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detect genomic DNA contamination. Samples were run in dupli-
cate and the results were analysed using the Pfaffl method
(Pfaffl, 2001). Relative gene expression levels were determined
by normalizing against human glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) mRNA levels, and data were pre-
sented as a fold difference in comparison with an uninfected
reference sample. For assessing expression in vivo, the
uninfected comparator consisted of cDNA synthesized from
pooled purified RNA extracted from biopsies of 10 randomly
selected H. pylori-negative patients. For in vitro analysis, RNA
was purified from epithelial cells cultured under different condi-
tions for 24 h. The uninfected negative controls in each experi-
ment were taken as the negative comparator. A commercial
human cDNA standard (BD Biosciences; Oxford, UK) was
included as a positive control in all assays.
Quantification of hβD1 mRNA was carried out using a
QuantiTECT™ SYBR Green PCR kit with commercial primers
(QIAGEN). Amplification of hβD2 was carried out over 45 cycles of
15 s at 95°C, 30 s at 61°C and 30 s at 72°C (Primer sequences:
hβD2 forward: 5′-CTGATGCCTCTTCCAGGTGTTT-3′; hβD2
reverse: 5′-GAGACCACAGGTGCCAATTTG-3′; GAPDH for-
ward: 5′-CCACATCGCTCAGACACCAT-3′; GAPDH reverse:
5′-GGCAACAATATCCACTTTACCAGAGT-3′). No-template con-
trols were included in each run.
Inhibitor studies
Epithelial cells were pre-treated with specific chemical inhibitors
(Merck, Nottingham, UK) for 60 min prior to and during bacterial
stimulation. The drugs used were U0126 (10 μM; MEK 1 inhibitor),
SP600125 (10 μM; JNK inhibitor), SB203586 (10 μM; p38 inhibi-
tor) and 6-amino-4-(4-phenoxyphenylethylamino)quinazoline
(1 μM; NF-κB activation inhibitor). Cultures were incubated as
described above and defensin expression levels were assessed.
As a positive control inducer of NF-κB activation (Robinson et al.,
2008), cells were treated with 50 ng ml−1 recombinant TNFα
(PeproTech).
siRNA transfections
Validated siRNA duplexes targeting NFKB1, RELA and MAPK1
mRNA (QIAGEN) were prepared according to the manufacturer’s
instructions. Non-silencing AllStars Hs Negative Control siRNA
and AllStars Hs Cell Death Control siRNA (positive control)
(QIAGEN) were tested in parallel. Epithelial cells were seeded at
1 × 105 per well in 24-well plates and treated with 10 nM siRNA
suspended in HiPerfect transfection regent (QIAGEN). Controls
were treated with HiPerfect only, or PBS. The cells were incu-
bated for 48 h at 37°C in 5% CO2, when a high degree of cell
death was observed in the positive control wells. This siRNA
construct targets genes that are indispensable for cell survival,
thus cell death confirmed successful transfection. NFKB1, RELA
and MAPK1 gene knock-down was confirmed by Western blot-
ting (Fig. S1) using rabbit antibodies against NF-κB p50 (Cell
Signaling Technology, MA, USA), NF-κB p65 (Millipore, MA,
USA), MAPK1/ERK (Source BioScience UK) and actin (Sigma-
Aldrich), with an anti-rabbit IgG-peroxidase conjugate (Sigma-
Aldrich) and chemiluminescent ECL substrate (GE Healthcare,
UK). Medium was removed from the wells before infecting with
H. pylori for a further 24 h.
Statistical analysis
Statistical analyses were carried out using GraphPad Prism 6
software. A P value ≤ 0.05 was taken as indicative of a significant
difference. In vivo data were displayed in box-and-whisker plots,
and compared using a Mann–Whitney U test or, for multiple
parameters, Kruskal–Wallis tests with a post hoc Dunn’s multiple
comparison. In vitro data were described using means and stand-
ard deviations, and comparisons between groups were made
using one-way ANOVA with a Dunnett’s post hoc test for multiple
variates.
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Supporting information
Additional Supporting Information may be found in the online
version of this article at the publisher’s web-site:
Fig. S1. Confirmation of gene silencing in AGS cells treated with
siRNA duplexes by Western blotting. Cells seeded in 24-well
plates were transfected with siRNA to target expression of
NFKB1, RELA, and MAPK1. Non-silencing negative control
duplexes (Neg) were also used. After 48 h, cells were harvested
into SDS-PAGE sample buffer. Western blots were probed,
stripped and re-probed using antibodies against NF-κB p50
(NFKB1 gene product), NF-κB p65 (RELA gene product),
MAPK1/ERK and beta actin.
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